EXHIBIT 10.31



 






EXHIBIT 10.31


Portions of this agreement
have been omitted and separately filed with the SEC with a request
for confidential treatment. The location of those omissions have been
noted by [**].



DISTRIBUTION AGREEMENT

FOR FLUVIRALTM (INFLUENZA VACCINE)




between




ID BIOMEDICAL CORPORATION




and





HENRY SCHEIN, INC.








 






TABLE OF CONTENTS




	 	 	 	 	 	 	 
	 	 	 	 	Page
	 
	 	 	 	 	 	 
	1.

	 	DEFINITIONS
	 	 	1	 
	 
	 	 	 	 	 	 
	2.

	 	APPOINTMENT AND AUTHORITY OF DISTRIBUTOR
	 	 	3	 
	 
	 	 	 	 	 	 
	3.

	 	SUPPLY AND PURCHASE OF PRODUCT
	 	 	4	 
	 
	 	 	 	 	 	 
	4.

	 	PURCHASE PRICE AND PAYMENT
	 	 	7	 
	 
	 	 	 	 	 	 
	5.

	 	DELIVERY OF PRODUCT
	 	 	7	 
	 
	 	 	 	 	 	 
	6.

	 	MARKETING OF PRODUCT
	 	 	9	 
	 
	 	 	 	 	 	 
	7.

	 	REGULATORY COMPLIANCE
	 	 	10	 
	 
	 	 	 	 	 	 
	8.

	 	TRADEMARKS AND OTHER INTELLECTUAL PROPERTY
	 	 	12	 
	 
	 	 	 	 	 	 
	9.

	 	CONFIDENTIAL INFORMATION; PUBLICITY
	 	 	13	 
	 
	 	 	 	 	 	 
	10.

	 	FORCE MAJEURE
	 	 	14	 
	 
	 	 	 	 	 	 
	11.

	 	WARRANTIES OF IDB AND HSI
	 	 	15	 
	 
	 	 	 	 	 	 
	12.

	 	INDEMNIFICATION OBLIGATIONS OF IDB AND HSI
	 	 	17	 
	 
	 	 	 	 	 	 
	13.

	 	INSURANCE OBLIGATIONS OF IDB AND HSI
	 	 	18	 
	 
	 	 	 	 	 	 
	14.

	 	LIMITATION OF LIABILITY
	 	 	18	 
	 
	 	 	 	 	 	 
	15.

	 	TERM AND TERMINATION
	 	 	19	 
	 
	 	 	 	 	 	 
	16.

	 	NOTICES
	 	 	21	 
	 
	 	 	 	 	 	 
	17.

	 	ASSIGNMENT
	 	 	21	 
	 
	 	 	 	 	 	 
	18.

	 	GOVERNING LAW, JURISDICTION AND VENUE
	 	 	21	 
	 
	 	 	 	 	 	 
	19.

	 	MISCELLANEOUS
	 	 	22	 






	 	 	 
	SCHEDULES:

	 	 
	SCHEDULE 1

	 	MINIMUM QUANTITY; PURCHASE PRICE AND ADJUSTMENT; RESALE TO OTHER DISTRIBUTORS; AND
PAYMENT TERMS
	SCHEDULE 2

	 	TRADEMARK(S)
	SCHEDULE 3

	 	COMMITMENTS TO GOVERNMENT OF CANADA
	SCHEDULE 4

	 	ADVERSE REACTION REPORTING
	SCHEDULE 5

	 	PRODUCT RECALL PROCEDURE






i








 





Portions of this agreement have been omitted and separately filed with the SEC with a request for confidential treatment. The location of those omissions have been noted by [**].





DISTRIBUTION AGREEMENT




      This DISTRIBUTION AGREEMENT (together with the attachments and exhibits hereto, the
“Agreement”) is entered into as of December 2, 2004 (the “Effective Date”) by and between ID
BIOMEDICAL CORPORATION, a corporation organized and existing under the laws of the Company Act of
British Columbia and having its principal office at 1630 Waterfront Centre, 200 Burrard Street,
Vancouver, BC V6C 3L6 Canada (“IDB”), and HENRY SCHEIN, INC., a corporation organized and existing
under the laws of the State of Delaware, USA and having its principal office at 135 Duryea Road,
Melville, NY 11747 USA (“HSI”).



WHEREAS:




      A. IDB develops and manufactures proprietary vaccines, including an injectable vaccine for the
prevention of influenza virus infection in humans that is approved in Canada and under development
for the U.S. market, and has all right, title and interest in the Product (as defined below); and



      B. HSI is a leading distributor of vaccines in the Territory (as defined below), with
expertise in sales, marketing and cold chain logistics, and desires to and has agreed to act as
non-exclusive distributor of IDB for sales of Product in the Territory; and



      C. IDB is willing to supply HSI with Product for resale in the Territory, and HSI is willing
to purchase Product for resale in the Territory, on the terms and conditions of this Agreement.



      Now, therefore, in consideration of the foregoing premises and the mutual covenants and
undertakings set forth below, the Parties hereby agree as follows:



1. DEFINITIONS




      1.1 “Affiliate” means, with respect to a Party, any corporation or other business entity that,
directly or indirectly, is Controlled by, Controls or is under common Control with such Party, but
only for so long as such relationship exists. “Control,” as used in this Section 1.1, means having
the power to direct, or cause the direction of, the management and policies of any entity, whether
through ownership of voting securities, by contract, or otherwise.



      1.2 “Average Sell Price” shall mean [**]




      1.3 “Commencement Date” shall mean the date that IDB receives the initial Marketing
Authorization from the Regulatory Authority required to market Product in the Territory in the
first Flu Season, which shall in no event be later than April 1, 2008 or, if such initial Marketing
Authorization is received prior to such date, then the Commencement Date shall be as provided in
Section 7.2 below.



[**] - Confidential or
proprietary information redacted.

 








 





      1.4 “Confidential Information” shall mean any confidential or proprietary information
(including, without limitation, know-how, trade secrets, and other confidential or proprietary
information relating to Product research, development, manufacturing, marketing, sales and
financial information related thereto), whether oral, visual or written, that is disclosed by one
Party hereto (the “Disclosing Party”) to the other (the “Receiving Party”) in connection with this
Agreement, including, without limitation, reports provided by HSI to IDB pursuant to Section 2.3
below.



      1.5 “Flu Season” shall mean the period from approximately October 1 through March 31.



      1.6 “Intellectual Property” shall mean any patent, copyright, trade secret, know-how,
trademark, tradename, design right, moral rights or other intellectual property right related to
the Product under the laws of any governmental authority, domestic or foreign, including all
applications and registrations related to any of the foregoing.



      1.7 “Marketing Authorization” shall mean the Biologics License Application (BLA) approved by
the Regulatory Authority and required to distribute or to deliver for distribution Product lawfully
in the Territory, together with any renewals and replacements thereof and amendments thereto.



      1.8 “Minimum Doses” shall mean the number of doses of Product set forth in clause (i) of
Paragraph 1 of Schedule 1 to this Agreement.



      1.9 “Minimum Percentage” shall mean the percentage set forth in clause (ii) of Paragraph 1 of
Schedule 1 to this Agreement.



      1.10 “Minimum Quantity” shall mean the quantity of Product that the Parties have agreed shall
be the minimum quantity to be purchased by HSI from IDB for each Flu Season, as specified in
Paragraph 1 of Schedule 1 to this Agreement, as such Minimum Quantity may be modified from time to
time in accordance with the terms of this Agreement; such Minimum Quantity shall be subject to
IDB’s annual influenza vaccine commitments and pandemic commitments to the Government of Canada
during the Term (as provided in Section 3.2).



      1.11 “Net Sales Revenue” shall mean [**]




      1.12 “Other Distributors” shall mean sub-distributors, wholesalers and other resellers to
which HSI may sell Product in accordance with Paragraph 3 of Schedule 1 to this Agreement.



      1.13 “Parties” shall mean IDB and HSI, and “Party” shall mean either of them as the context
indicates.



      1.14 “Product” shall mean IDB’s injectable influenza virus vaccine product [**]




      1.15 “Purchase Price” shall mean the price to be paid by HSI to IDB for all doses of Product
supplied to HSI under this Agreement, as set forth in Paragraph 2 of Schedule 1 to this Agreement.



[**] - Confidential or
proprietary information redacted.



2








 





      1.16 “Regulatory Authority” shall mean the United States Food and Drug Administration, an
agency of the U.S. Department for Health and Human Services, and any successor agency thereto.



      1.17 “Shipping Point” shall mean a single distribution center located in the continental
United States to which Product shall be shipped under this Agreement, which single distribution
center shall be nominated by HSI in its discretion from time to time, but not more than once for
any given Flu Season.



      1.18 “Specifications” shall mean the specifications provided in the Marketing Authorization,
including, but not limited to, those specifications to ensure that the Product is and will continue
to be safe, pure and potent, as such specifications may be modified from time to time in accordance
with the terms of this Agreement or so as to comply with the requirements of the Regulatory
Authority.



      1.19 “Term” shall mean the duration of this Agreement as specified in Section 15.1.



      1.20 “Territory” shall mean the United States of America, including all fifty (50) states and
the District of Columbia, and all of its territories and possessions.



      1.21 “Third-Party Vaccine Products” shall mean injectable influenza virus vaccine products,
manufactured by or on behalf of any person or entity other than IDB or its Affiliates, [**]



      1.22 “Trademark(s)” shall mean the trademark(s), trade names, service marks and logos
identified in Schedule 2 to this Agreement, and such other trademark(s), trade names, service marks
and logos as may be identified and indicated to HSI by IDB in writing from time to time during the
Term.



      1.23 “Transfer Price” shall have the meaning given in Paragraph 2(B) of Schedule 1 to this
Agreement.



2. APPOINTMENT AND AUTHORITY OF DISTRIBUTOR




      2.1 Subject to the terms and conditions of this Agreement, IDB hereby appoints HSI as its
non-exclusive distributor for the resale of Product in the Territory, and HSI hereby agrees to act
in that capacity beginning on the Commencement Date. HSI hereby agrees that [**]. HSI shall have
the non-exclusive, non-assignable (except in accordance with Section 17 below), non-licensable and
non-sublicensable right, after the Commencement Date and throughout the Term, to promote, sell,
market and distribute Product to customers (either directly or through Affiliates or Other
Distributors) in the Territory; provided, however, HSI shall not resell to Other Distributors more
than the allowable maximum number of doses of Product specified in Paragraph 3 of Schedule 1. HSI
may, on and after the Commencement Date, describe itself as a distributor of Product for IDB in the
Territory but it shall not hold itself out as IDB’s agent or representative or as otherwise being
authorized to bind IDB in any way. IDB hereby grants to each of HSI’s Affiliates and Other
Distributors the rights granted to HSI in this Section 2.1 solely to the extent necessary to
perform their obligations with respect to the Product.



[**] - Confidential or
proprietary information redacted.


3








 





      2.2 HSI shall actively promote, distribute and sell Product only within the Territory, and
neither HSI nor its Affiliates or Other Distributors shall promote or solicit orders for Product or
donate, sell, offer to sell or otherwise distribute Product outside the Territory, or where they
ought reasonably to be aware that the ultimate destination for Product is outside the Territory.
HSI and its Affiliates and Other Distributors and their respective employees and agents shall not
promote Product for any indications not approved for such Product by the Regulatory Authority. HSI
shall forward to IDB all inquiries relating to Product from customers or potential customers
outside the Territory.



      2.3 As Product distributor, HSI shall determine the prices and other terms and conditions
under which it offers Product for sale and sells Product to customers within the Territory. On or
prior to the Commencement Date, HSI shall provide IDB with a resale certificate in such form, and
containing such information, as required by IDB. On a monthly basis during the Term, beginning
after the Commencement Date, HSI shall provide a detailed written report to IDB, in a mutually
agreeable format, describing [**]. HSI shall deliver such reports to IDB in connection with the
monthly meetings conducted pursuant to Section 6.3. Notwithstanding the foregoing, HSI shall not
be required to identify names or addresses of customers of Product or Third-Party Vaccine Products
and shall not be required to provide information which HSI is prohibited by contract or law from
providing to third parties.



      2.4 HSI shall not make any alterations or knowingly permit any alterations to be made to
Product without IDB’s express written consent, which consent may be withheld in IDB’s sole
discretion.



      2.5 The Parties acknowledge and agree that IDB may sell Product to any United States
governmental agency or body at any time between the Effective Date and the Commencement Date under
a special procurement process to address influenza vaccine shortages or other immediate needs of
the U.S. government, and such sales shall not be subject to the terms of this Agreement; provided,
however, that IDB may indicate to the U.S. government a preference for distribution of some
quantity of Product under such circumstances by and through HSI, although IDB shall not be deemed
to be in breach of this Agreement or to have any liability to HSI, and HSI shall have no right to
terminate this Agreement or exercise any other remedies against IDB, if IDB does not indicate such
preference to the U.S. government or the U.S. government fails to distribute Product under such
circumstances by or through HSI.



3. SUPPLY AND PURCHASE OF PRODUCT




      3.1 Subject to Section 3.2 and Paragraph 2(C) of Schedule 1 to this Agreement, IDB agrees to
use commercially reasonable efforts to develop, manufacture, apply for Marketing Authorization of,
apply for the release of and deliver to HSI, on or before the delivery dates specified in Schedule
1, the Minimum Quantity of Product as a final, packaged product. HSI hereby commits to purchase
the Minimum Quantity of Product provided by IDB to HSI for each Flu Season from and after the
Commencement Date during the Term, for the Purchase Price described in Schedule 1, provided
delivery and release of the Minimum Quantity occurs on or before [**] of such Flu Season. IDB
agrees to notify HSI promptly of any delay in the manufacturing and shipping schedule, the cause of
such delay and the anticipated extent of such delay, or in the event IDB is unable to manufacture
(and the cause for such inability to



[**] - Confidential or
proprietary information redacted.


4








 






manufacture) some or all of the Minimum Quantity of Product for any given Flu Season.
Recognizing the difficulties involved in vaccine manufacturing, the Parties acknowledge and agree
that IDB shall not be deemed to be in breach of this Agreement or to have any liability to HSI, and
HSI shall have no right to terminate this Agreement under this Section 3.1 or exercise any other
remedies against IDB, if IDB fails to manufacture any or all of the Minimum Quantity of Product for
any given Flu Season provided that IDB has used commercially reasonable efforts to develop,
manufacture, apply for Marketing Authorization of, apply for the release of and deliver to HSI, on
or before the delivery dates specified in Schedule 1, the Minimum Quantity of Product as a final,
packaged product. [**]



      3.2 Notwithstanding anything to the contrary in this Agreement, HSI acknowledges and agrees
that IDB’s obligation to supply the Minimum Quantity of Product to HSI under this Agreement is
subject to, and the Minimum Quantity shall be reduced by, IDB’s contractual annual commitments to
provide Product to the Government of Canada and additional contractual commitments to provide
Product to the Government of Canada in the event of influenza pandemics in Canada, if any, which
commitments shall have priority over IDB’s commitments to HSI hereunder. Such commitments to the
Government of Canada are described further on Schedule 3. The Parties agree that IDB shall not be
deemed to be in breach of this Agreement or to have any liability to HSI, and HSI shall have no
right to terminate this Agreement, in the event IDB is unable to supply HSI with the Minimum
Quantity of Product because of such commitments to the Government of Canada. IDB shall keep HSI
informed, in the monthly meetings described in Section 6.3, of the quantity (if any) of Product
necessary to meet such commitments to the Government of Canada for a given Flu Season and the
impact on the Minimum Quantity of Product available to HSI with respect to such Flu Season.



      3.3 Except as otherwise specified in Section 3.4 below, IDB agrees that, with respect to the
timing of shipment of a given quantity of Product into the Territory, IDB will allocate such
quantity of Product among HSI and IDB’s other distributors in the Territory on a pro rata basis,
based on HSI’s and each such other distributor’s respective Minimum Percentage. Thus, IDB will
supply HSI with a percentage of each lot of Product that is shipped into the Territory that is
approximately equal to HSI’s Minimum Percentage, subject to the overall Minimum Quantity
limitations set forth in this Agreement.



      3.4 HSI shall be granted a first right of refusal to acquire a percentage of increased
production of Product as provided in this Section 3.4. [**]



      3.5 All Product shall be packaged and labeled for sale and delivered by IDB to HSI in
accordance with the regulations of the Regulatory Authority, such packaging indicating that the
Product is manufactured by IDB and that the Trademarks are registered trademarks of IDB. Subject
to compliance with applicable regulations of the Regulatory Authority, IDB may at any time withdraw
the Product from the market or alter the Specifications as it deems necessary or appropriate and/or
as may be required by the Regulatory Authority, including without limitation changes in design,
production or packaging of Product.



      3.6 IDB shall be responsible for exporting Product from any location in which IDB may
manufacture or have manufactured Product and shall obtain any necessary export licenses required
for such export. IDB shall be responsible for obtaining any necessary licenses or




[**] - Confidential or
proprietary information redacted.


5








 






approvals of applicable regulatory agencies in the Territory required for the importation of
Product into the Territory and for the payment of all duties, fees and charges required for such
importation; provided, that, HSI shall be the importer of record of Product into the
Territory and HSI shall cooperate with and assist IDB, upon IDB’s written request and at IDB’s
expense, in obtaining approvals of regulatory agencies in the Territory required for the
importation of Product into the Territory.



      3.7 The Regulatory Authority’s release of each lot of Product is necessary before HSI is
allowed to distribute Product. The Parties recognize that the timing for obtaining Regulatory
Authority release is uncertain. However, IDB shall use its commercially reasonable efforts to
obtain the necessary Regulatory Authority releases as soon as reasonably possible each Flu Season
and, to the extent reasonably possible, by [**] of each Flu Season after the Commencement Date
for [**] of the Minimum Quantity and by [**] of each Flu Season after the Commencement Date for
[**] of the Minimum Quantity; provided, that, if and to the extent that Product is not
manufactured or available for release, or that some or all Regulatory Authority releases are not
obtained, on or before either [**] in a given Flu Season after the Commencement Date,
irrespective of the reason therefor, (i) IDB shall not be deemed to have breached any obligations
under this Agreement or to be liable to HSI hereunder provided that IDB has used its commercially
reasonable efforts to obtain the necessary Regulatory Authority releases as soon as reasonably
possible each Flu Season, and (ii) notwithstanding the provisions of Section 10 below, if [**] of
the Minimum Quantity of Product is not released by [**] in such Flu Season, HSI shall not be
obligated to purchase the amount of Product that was not released by such date. Notwithstanding
the foregoing, HSI may elect to purchase Product released after [**] (provided release is
obtained by a date acceptable to HSI), in which case it shall notify IDB in writing of HSI’s
decision to acquire Product released after [**] within five (5) business days after [**] ,
which notice shall include the quantity of Product HSI desires to purchase and the acceptable post-
[**] release date for such Product. If IDB reasonably believes such release date is achievable,
IDB shall use its commercially reasonable efforts to obtain Product release by such date (or by
such other date as the Parties may mutually agree in writing). HSI shall return to IDB (at IDB’s
expense) any Product not released by [**] that HSI decides not to purchase. HSI shall pay IDB
the Purchase Price for all Product released by [**] , as well as all Product released after
[**] that HSI elects to purchase, in accordance with the terms and conditions of this Agreement,
with no right to return such Product to IDB (except only as set forth in Sections 5.2 and 5.3) even
if HSI is unable to sell such Product.



      3.8 IDB will provide HSI with a copy of IDB’s key clinical development milestones for Product
in the Territory (the “Milestones”) promptly after execution of this Agreement, which Milestones
shall be subject to modification by IDB from time to time. IDB will provide HSI with written
reports regarding progress made with respect to the Milestones (as modified) as of June 30, 2005,
December 31, 2005, and quarterly thereafter through December 31, 2006. HSI agrees that the
Milestones and progress reports are being provided by IDB for informational purposes only, and that
IDB shall not be deemed to be in breach of this Agreement or to have any liability to HSI, and HSI
shall have no right to terminate this Agreement under this Section 3.8 or exercise any other
remedies against IDB, in the event the development of Product does not proceed in accordance with
the Milestones. HSI further agrees that the Milestones and all progress reports shall be
considered Confidential Information of IDB under this Agreement.




[**] - Confidential or
proprietary information redacted.


6








 





      3.9 [**]



4. PURCHASE PRICE AND PAYMENT




      4.1 HSI shall pay IDB the Purchase Price for the Minimum Quantity of Product, and all other
Product supplied by IDB to HSI under this Agreement, as the Purchase Price is described and
calculated in accordance with Paragraph 2 of Schedule 1.



      4.2 IDB may invoice HSI at any time after Product has been delivered to the Shipping Point.
Payment in full of the Transfer Price of all Product in each shipment shall be due and paid by HSI
to IDB within thirty (30) days after the later of (i) the date of delivery of such Product to the
Shipping Point or (ii) the date of release of such Product by the Regulatory Authority.
Reconciliation and payment or credit of the final Purchase Price (the Transfer Price as adjusted in
accordance with Paragraph 2(B) of Schedule 1) shall be made as provided in Paragraph 2(D) of
Schedule 1. Should HSI fail to pay IDB any amount due IDB on or before the due date for payment,
HSI shall pay IDB the full amount due plus interest on such unpaid amount from its original due
date until the date IDB receives full payment, such interest to be at the rate specified in
Paragraph 5 of Schedule 1. For the avoidance of doubt, in the event that Product is delivered to
HSI and invoiced by IDB, but subsequently is properly rejected by HSI in accordance with Sections
5.2 and 5.3 of this Agreement, then HSI shall pay the full Transfer Price, but IDB shall give
appropriate credit to HSI unless the rejected Product is replaced by IDB at IDB’s expense in
accordance with Section 5.3.



      4.3 During the term of this Agreement and for a period of three (3) years thereafter, HSI and
its Affiliates shall keep accurate books and records with respect to the sale and distribution of
Product in accordance with U.S. generally accepted accounting principles (“GAAP”) consistently
applied and in sufficient detail to enable IDB to determine the correctness of all payments made to
IDB hereunder. Upon written request by IDB, HSI shall permit an independent certified public
account or IDB in-house auditor or accountant (“Accountant”) (to be determined and selected by IDB
and reasonably acceptable to HSI), to inspect HSI’s books, records and facilities, and copy such
books and records, to the extent such Accountant reasonably deems necessary or appropriate for the
sole purposes of verifying the completeness and accuracy of the reports delivered and payments made
under this Agreement and ascertaining HSI’s compliance with its obligations under this Agreement.
The Accountant’s report based on such inspection shall be limited to a detailed report on those
subjects. [**] HSI will pay IDB the amount of any such deficiency within thirty (30) days of the
date of the invoice therefor, and shall pay interest at the rate specified in Paragraph 5 of
Schedule 1 for any past due amounts.



5. DELIVERY OF PRODUCT




      5.1 Subject to HSI’s satisfaction of its importation obligations under Section 3.6, IDB agrees
to deliver all Product ordered by HSI hereunder FOB Shipping Point.



      5.2 All Product is shipped on a non-returnable basis except only as set forth in Sections 3.7
and 5.3 and except if there is a Product recall. HSI shall pay IDB the Purchase Price for all
Product delivered to HSI and released by the Regulatory Authority even if HSI is unable




[**] - Confidential or
proprietary information redacted.


7








 






to sell such Product, subject only to HSI’s right to reject Product as provided below. Not
later than [**] days after its receipt of each shipment of Product at the Shipping Point, and
sooner if reasonably possible, HSI shall notify IDB as provided in Section 5.3 of any basis for
rejecting any such Product (the only bases for rejection being as specified in Section 5.3). If
HSI fails to give such notice to IDB within such period, then such Product shall be deemed to be
finally accepted by HSI. Notwithstanding the foregoing, if HSI thereafter discovers a latent
defect which could not readily be identified upon a reasonable inspection of Product at the time of
delivery to the Shipping Point, and such latent defect constitutes a Defective Product (as defined
in Section 11.4 below), HSI shall inform IDB of such Defective Product within five (5) business
days of such discovery, and the provisions of Section 5.3 shall apply.



      5.3 To reject Product, HSI shall, within the rejection period specified in Section 5.2, notify
IDB of its rejection in writing, describing in detail the basis for such rejection (which must be
either, and shall be limited to, (i) a Defective Product as defined in Section 11.4 below, or (ii)
physical damage to Product in the course of shipment to HSI) and the amount of Product affected,
and request a return authorization (“RA”) number. IDB shall provide the RA number to HSI within
[**] days after receipt of the request. Within [**] days after HSI’s receipt of the RA number,
HSI shall return to IDB the rejected Product, freight prepaid, with the RA number displayed on the
outside of the carton. IDB reserves the right to refuse to accept any rejected Product that does
not bear an RA number on the outside of the carton. As promptly as possible, and within [**]
days after receipt of properly rejected Product if reasonably possible, IDB shall use commercially
reasonable efforts to replace the Product, at its expense, as provided in Section 5.4. IDB shall
pay the shipping charges back to HSI for properly rejected Product; otherwise, HSI shall be
responsible for the shipping charges.



      5.4 In the event HSI rejects any shipment of Product in accordance with Sections 5.2 and 5.3
or in the event of failure to obtain Product releases from the Regulatory Authority by [**] of a
given Flu Season, then IDB shall use commercially reasonable efforts to provide, but shall not
guarantee to provide, replacement Product, subject in all respects to IDB’s commitments to the
Government of Canada as provided in Section 3.2. In the event IDB does not supply replacement
Product to HSI within a reasonable period (at least [**] days) and HSI notifies IDB in writing
that it elects not to wait beyond such period for replacement Product, then IDB shall credit HSI
for the amount, if any, previously paid by HSI for such rejected or unreleased Product, but IDB
shall not be deemed to be in breach of this Agreement or to have any liability to HSI because it
failed to supply replacement Product; provided, however, that if HSI has not yet paid for such
rejected or unreleased Product and IDB fails to supply replacement Product, HSI shall have no
obligation to pay for such rejected or unreleased Product. If IDB will not be able to supply
replacement Product until after [**] of a given Flu Season, then HSI may elect, at its option, to
accept such replacement Product after such date or to receive a credit for the amount, if any,
previously paid by HSI for the rejected or unreleased Product, provided that HSI notifies IDB in
writing of its election within five (5) business days after [**] . If HSI wrongfully rejects
Product or wrongfully fails to take delivery of any shipment of Product, then IDB shall be entitled
to invoice HSI for the Transfer Price and then the Purchase Price of such Product as set forth in
Schedule 1, together with the cost of disposing of such Product, if applicable, and HSI shall pay
such invoiced amount within thirty (30) days of the invoice date.




[**] - Confidential or
proprietary information redacted.


8








 





      5.5 Risk of loss of or damage to Product supplied by IDB to HSI shall pass to HSI at the time
Product is delivered to the Shipping Point. If HSI properly rejects Product in accordance with
Sections 5.2 and 5.3, then risk of loss of or damage to Product will pass back to IDB upon delivery
by HSI to the first return carrier. Title to Product shall pass to HSI at the time Product is
delivered to the Shipping Point. If any shipment of Product is delivered to the Shipping Point
before such Product is released by the Regulatory Authority, HSI shall quarantine such Product, at
its sole cost, until such Product is released. HSI shall have title to, and shall bear all
responsibility and liability with respect to, all Product after it is delivered to the Shipping
Point, including all Product in quarantine.



6. MARKETING OF PRODUCT




      6.1 Notwithstanding anything to the contrary in this Agreement, HSI hereby agrees that [**].
Without limiting HSI’s obligations under this Agreement, HSI may promote, sell and distribute
Third-Party Vaccine Products provided that such promotion, sale and distribution are consistent
with this Section 6.1 and HSI’s other obligations under this Agreement. [**]



      6.2 Without limiting its other obligations under this Agreement, HSI shall exercise
commercially reasonable efforts to actively promote the use and sale of Product and the use of the
FluviralTM brand name (or other Trademark as may be indicated by IDB) throughout the
Territory. In this context, “commercially reasonable efforts” means at least the quality and
quantity of efforts that HSI does or would use to promote the use and sale, and expand the sale, of
any influenza vaccine originated or sold by HSI that is distributed in substantially the same
quantities as the quantities of Product contemplated in this Agreement (with at least the same
level of advertising, promotion and sales support). IDB agrees to provide HSI with such technical
and clinical data as HSI may reasonably require in order to promote, distribute and sell Product in
the Territory, subject to the provisions of Section 9.



      6.3 HSI and IDB shall convene by telephone, videoconference or in person, on a quarterly
basis—and more frequently if reasonably requested by either Party— until the initial Marketing
Authorization for Product is received and then monthly thereafter—and more frequently if reasonably
requested by either Party—to discuss (as may be relevant at the time) regulatory developments
affecting Product, HSI’s marketing plan, strategy and marketing and sales efforts proposed for
Product for a given Flu Season, IDB’s Product supply issues, if any, IDB’s Product commitments to
the Government of Canada for a given Flu Season, as described in Section 3.2, and such other
relevant issues as either Party may propose. [**] Each Party shall consider in good faith the
views expressed by the other Party during such meetings.



      6.4 HSI shall, and shall require its Affiliates and Other Distributors to, conduct all
promotion, marketing, distribution and sale of Product, including, without limitation, handling,
inventory and storage of Product, in compliance with all applicable laws and regulations and all
applicable rules and requirements of IDB, including, without limitation, cold chain requirements
for Product as set forth in the package insert for Product each Flu Season, as the same may be
updated by IDB from time to time, and as otherwise may be required or reasonably prudent. When
promoting, marketing and selling Product, HSI shall, and shall require its Affiliates and Other
Distributors to: (i) provide IDB copies of all labels, promotion and marketing materials related
to Product promptly upon IDB’s request; (ii) make no false or misleading statements to



[**] - Confidential or
proprietary information redacted.


9








 






customers or others regarding IDB or Product, or make any representations, warranties or
guarantees with respect to Product other than those printed on the Product packaging or labeling
expressly included in Product information, in each case as provided or approved by IDB in writing
in advance and as permitted by law; (iii) comply with the procedures and requirements for adverse
reaction reporting (“Adverse Reaction Reporting”), which Adverse Reaction Reporting shall be as
required by applicable law or regulation and shall be mutually agreed upon in writing by the
Parties as promptly as practicable following receipt of appropriate regulatory approval and
Marketing Authorization for Product in the Territory (and prior to any distribution of Product by
HSI pursuant to this Agreement). (Once finalized, the Adverse Reaction Reporting will be attached
hereto as Schedule 4); (iv) in the event of a Product recall, perform such recall in accordance
with Section 11.4 and the applicable Product recall procedure (“Product Recall Procedure”), subject
to IDB’s prior written agreement to the recall and HSI’s ongoing consultation with IDB regarding
the recall. (The Product Recall Procedure will be mutually agreed upon in writing by the Parties
as promptly as practicable following receipt of appropriate regulatory approval and Marketing
Authorization for Product in the Territory (and prior to any distribution of Product by HSI
pursuant to this Agreement). (Once finalized, the Product Recall Procedure will be attached hereto
as Schedule 5); and (v) communicate with the Regulatory Authority concerning Product only with
IDB’s prior written consent (and, if requested by IDB, IDB’s participation in such communication).
If the Regulatory Authority requests information from HSI regarding Product, HSI shall keep IDB
fully informed of all such communications, provide IDB with copies of all such written
communications, consult with IDB regarding responses thereto, and allow IDB, at its request, to
control or to participate in formulating responses thereto (all in compliance with applicable laws
and regulations).



7. REGULATORY COMPLIANCE




      7.1 The Parties acknowledge that, as of the Effective Date of this Agreement, the Product has
not received Marketing Authorization from the Regulatory Authority. IDB shall, at its expense, use
commercially reasonable efforts to apply for, obtain and maintain in force the Marketing
Authorization(s) required to permit the supply, distribution and resale of Product in the Territory
in accordance with this Agreement. HSI shall give such reasonable assistance as IDB may require
from time to time in pursuing such applications for the Marketing Authorization. IDB shall
exercise commercially reasonable efforts to obtain the Marketing Authorization for Product in the
Territory as soon as reasonably practicable, but in any event on or before April 1, 2008 for the
2008/2009 Flu Season and by [**] in subsequent Flu Seasons. For the avoidance of doubt, IDB
gives no firm undertakings in relation to the grant of the Marketing Authorization by any date, or
at all, and, except for HSI’s right to terminate this Agreement as provided in Section 15.3.1, HSI
shall have no claim against IDB arising out of any failure to obtain the grant or renewal of the
Marketing Authorization.



      7.2 If IDB receives the initial Marketing Authorization on or before [**], 2005, the
Commencement Date shall be [**], 2005. If IDB receives the initial Marketing Authorization after
[**], 2005, then HSI shall have no obligation to acquire Product for the 2005/2006 Flu Season
provided, that, HSI may, by giving written notice to IDB within thirty (30) days after HSI
receives written notice that such initial Marketing Authorization has been received, elect to
acquire Product for the 2005/2006 Flu Season in which case the Commencement Date shall be the date
in 2005 as mutually agreed upon in writing by the Parties. Unless the Parties have



[**] - Confidential or
proprietary information redacted.


10








 






agreed upon such a 2005 Commencement Date, if IDB receives the initial Marketing Authorization
after [**], 2005 but on or before [**], 2006, the Commencement Date shall be [**], 2006. If IDB
receives the initial Marketing Authorization after [**], 2006, then HSI shall have no obligation to
acquire Product for the 2006/2007 Flu Season provided, that, HSI may, by giving written
notice to IDB within thirty (30) days after HSI receives written notice that such initial Marketing
Authorization has been received, elect to acquire Product for the 2006/2007 Flu Season in which
case the Commencement Date shall be the date in 2006 as mutually agreed upon in writing by the
Parties. Unless the Parties have agreed upon such a 2006 Commencement Date, if IDB receives the
initial Marketing Authorization after [**], 2006 but on or before [**], 2007, the Commencement Date
shall be [**], 2007. If IDB receives the initial Marketing Authorization after [**], 2007, then
HSI shall have no obligation to acquire Product for the 2007/2008 Flu Season provided,
that, HSI may, by giving written notice to IDB within thirty (30) days after HSI receives written
notice that such initial Marketing Authorization has been received, elect to acquire Product for
the 2007/2008 Flu Season in which case the Commencement Date shall be the date in 2007 as mutually
agreed upon in writing by the Parties. Unless the Parties have agreed upon such a 2007
Commencement Date or HSI has terminated this Agreement in accordance with Section 15.3.1 below, if
IDB receives the initial Marketing Authorization after [**], 2007 but on or before [**], 2008, the
Commencement Date shall be [**], 2008.



      7.3 IDB shall have the right (without liability to HSI) to terminate its obligations to supply
Product to HSI for any Flu Season upon notice to HSI if, as a result of any action taken by a
Regulatory Authority or any other governmental authority, it becomes impossible or commercially
impracticable for IDB to supply substantially all of the Minimum Quantity of Product for that Flu
Season in accordance with the terms of this Agreement. In such event, subject to Section 15.3,
this Agreement shall remain effective with respect to the supply of Product in subsequent Flu
Seasons.



      7.4 Unless the Regulatory Authority requires otherwise, the Marketing Authorization will be
issued in the name of and held by IDB. HSI shall give IDB prompt written notice of all changes to
the Marketing Authorization required by the Regulatory Authority of which it becomes aware. [**]



      7.5 HSI shall, at its expense, obtain and maintain in full force and effect throughout the
Term any and all licenses and approvals, other than the Marketing Authorization, necessary for the
storage, marketing, distribution and sale of Product in the Territory, in full compliance with all
applicable laws and regulations. HSI shall assume all responsibility for and shall comply with all
applicable laws and regulations concerning the inventory, storage, use, promotion, distribution and
sale of Products in the Territory and, correspondingly, for any damage, claim, liability, loss or
expense which IDB may suffer or incur by reason of said inventory, use, promotion, distribution and
sale, subject only to IDB’s obligations under Section 12.1. HSI shall not use any advertisement or
marketing material on, with respect to or relating to any Product unless such advertisement or
marketing material has first been submitted to and approved by IDB in advance in writing.



[**] - Confidential or
proprietary information redacted.


11








 





8. TRADEMARKS AND OTHER INTELLECTUAL PROPERTY




      8.1 All IDB Trademarks and derivatives thereof relating to Product, and all technology and
other Intellectual Property relating to Product and the goodwill associated therewith, are the sole
and exclusive property of IDB and/or its Affiliates. IDB hereby grants HSI permission to use the
Trademarks in the Territory for the limited purpose of HSI performing its rights and obligations
under this Agreement during the Term. Products shall be promoted, sold and distributed only under
the Trademarks. HSI shall ensure that each use of and reference to any of the Trademarks (by HSI,
its Affiliates or other Distributors) is accompanied by a statement that it is a registered
trademark of IDB. IDB may, in its sole discretion after consultation with HSI, modify or
discontinue the use of any Trademark and/or use one or more additional or substitute marks or
names, and HSI and its Affiliates and Other Distributors shall be obligated to do the same in
connection with marketing and selling Product. All representations of IDB’s Trademarks shall be
exact copies of those used by IDB or, if not, shall first be submitted to IDB for approval, which
approval shall not be unreasonably withheld or delayed. Upon written request, HSI shall give IDB
copies of examples of such usage in order to assess compliance with this Section.



      8.2 Neither HSI, its Affiliates, nor Other Distributors shall: (i) use the Trademarks in any
way that might prejudice their distinctiveness or validity or the goodwill of IDB therein; (ii) use
any Trademark in connection with the sale of any other product, or use any other trademark other
than the Trademarks, in connection with Product; (iii) modify Product or its labeling or packaging
or alter, obscure, or remove the Trademarks, indication of the source of origin, other means of
identification or other markings used on or in relation to Product; or (iv) at any time during or
after the term of this Agreement challenge or assist others to challenge the Trademarks or the
registration thereof, or use or make any application for registration in the Territory of any
trademarks or tradenames so resembling any trademark or tradename of IDB (including, without
limitation, any Trademark) as to be likely to cause confusion or deception.



      8.3 In the event HSI becomes aware of any infringement of, or threatened or suspected
infringement of, or challenge to any Trademark or other Intellectual Property of IDB, HSI shall
notify IDB immediately. IDB shall investigate any alleged violation and may take legal action as
it deems appropriate to resolve the issue and to prevent others from infringing on its Intellectual
Property rights within the Territory. At IDB’s reasonable request, and at IDB’s expense, HSI shall
cooperate with and assist IDB in connection with any such infringement.



      8.4 Except only for the limited rights as expressly permitted hereunder, and then only as
necessary for the proper performance of HSI’s obligations hereunder, HSI hereby acknowledges that
it shall acquire no rights, express or implied, in respect of any of IDB’s Intellectual Property,
including the tradenames or trademarks of IDB (including but not limited to the Trademarks) or of
the goodwill associated therewith and that all such rights and goodwill are, and shall remain,
vested in IDB.



      8.5 HSI will not do, nor will HSI allow or authorize its Affiliates, Other Distributors or
anyone else to do, any act which would or might invalidate or be inconsistent with the Intellectual
Property of IDB (including the Trademarks), and HSI shall not omit or allow or authorize anyone to
omit to do any act which, by its omission, would have that effect.



[**] - Confidential or
proprietary information redacted.


12








 





9. CONFIDENTIAL INFORMATION; PUBLICITY




      9.1 Both Parties recognize and acknowledge that each will have access to Confidential
Information of the other in connection with this Agreement. Other than as necessary to perform
their obligations under this Agreement, and except as otherwise permitted in this Section 9, both
Parties shall, during and after the Term keep all Confidential Information of the Disclosing Party
confidential and not disclose any such Confidential Information to any Third Party without the
express written consent of the Disclosing Party; and not use any Confidential Information of the
Disclosing Party for any purpose other than the performance of the Receiving Party’s obligations
under this Agreement.



      9.2 The Parties agree that the Confidential Information received from the Disclosing Party
hereunder shall not be disclosed to any employee, officer, or director of the Receiving Party or to
any of its Affiliates, except to those employees, officers, directors and Affiliates whose
responsibilities require such disclosure for purposes of performing the Receiving Party’s
obligations under this Agreement; provided that such employees, officers, directors and Affiliates
have entered into confidentiality agreements with provisions substantially similar to those set
forth in this Section 9.



      9.3 Confidential Information may be disclosed by a Receiving Party to the Regulatory Authority
or other governmental authority only to the extent necessary for the purposes contemplated by this
Agreement or as may be required by applicable law or regulation.



      9.4 Each Party agrees to use the same degree of care concerning the other Party’s Confidential
Information as it uses to protect its own confidential and proprietary technical information (but
no less than reasonable care) to prevent the unauthorized disclosure to any third party of the
Confidential Information received from the Disclosing Party hereunder. Except as expressly
provided in this Agreement, the Parties agree that they shall acquire no rights with respect to
Confidential Information of the other Party received hereunder.



      9.5 Confidential Information may be disclosed by a Receiving Party to a Third Party to the
extent that: (i) it is at the Effective Date, or thereafter becomes, public knowledge through no
act, omission or breach of this Agreement by the Receiving Party, its Affiliates or their
respective employees, officers or directors (provided that in doing so such Receiving Party shall
not disclose any Confidential Information which is not public knowledge); or (ii) it can be
reasonably shown by the Receiving Party, by written records in the Receiving Party’s possession
prior to disclosure, to have been known to the Receiving Party prior to disclosure by the
Disclosing Party; or (iii) such Confidential Information is required to be disclosed by law,
governmental or regulatory request or legal process; or (iv) to the extent such Confidential
Information is disclosed in connection with any legal or other dispute resolution proceedings
between the Parties hereto.



      9.6 The Receiving Party shall, within thirty (30) days following receipt of a request by the
Disclosing Party or termination or expiration of this Agreement, return and deliver (or if so
requested destroy and provide a certificate of destruction) to the Disclosing Party all copies of
Confidential Information of the Disclosing Party in the Receiving Party’s possession or under its
control; provided that each Party may retain one copy of such information solely for (i) archival



[**] - Confidential or
proprietary information redacted.


13








 






purposes, (ii) determination and reconciliation of the Parties’ respective rights and
obligations following such termination or expiration, or (iii) use in a dispute resolution
procedure that may arise between the Parties.



      9.7 Neither Party shall issue press releases or make public announcements relating to this
Agreement without the other Party’s prior written approval, which approval shall not be
unreasonably withheld or delayed; provided, however, that nothing in this Section shall impair
either Party’s compliance with any requirements of the Securities and Exchange Commission or the
national securities exchange or other stock market on which such Party’s securities are traded. In
connection with any filing by either Party of a copy of this Agreement with the Securities and
Exchange Commission (or the national securities exchange or other stock market on which such
Party’s securities are traded), the filing Party shall endeavor to obtain confidential treatment of
economic and trade secret information. Reasonably in advance of filing, the filing Party shall
provide to the other Party a copy of the proposed filing and the Parties shall work cooperatively
in good faith, taking into consideration the other Party’s suggestions, regarding the information
for which the filing Party will seek to obtain confidential treatment.



10. FORCE MAJEURE




      10.1 Neither Party shall be under any liability to the other for failure or delay in the
performance of any obligation hereunder or part thereof (other than obligations to pay money) to
the extent and for the period that such performance is prevented by reason of Force Majeure (as
defined below), provided that the Party claiming the benefit of this Section promptly begins, and
thereafter diligently pursues, the cure of such Force Majeure and gives written notice of the Force
Majeure to the other within thirty (30) days of the occurrence of the event of Force Majeure. For
purposes of this Agreement, “Force Majeure” shall mean any cause preventing or obstructing the
performance of this Agreement arising from or attributable to acts, events or circumstances beyond
the reasonable control of, and not caused by the negligence of, the Party affected, including but
not limited to epidemic of disease, Act of God, shortage of materials, war, acts of terrorism,
strikes or labor disputes, accidents, fire, breakdown of machinery, acts of government or other
legal authority (including any Regulatory Authority), riot or civil commotion. Notwithstanding the
foregoing, in the event IDB fails to deliver to the Shipping Point the Minimum Quantity, as such
Minimum Quantity may be adjusted as provided in this Agreement, for any given Flu Season due to an
event of Force Majeure, HSI shall have the option to extend the Term for one additional Flu Season
for each such Flu Season that the Minimum Quantity was not delivered, in which case, HSI shall
notify IDB in writing of HSI’s election to extend the Term within five (5) business days after the
last day of such Flu Season for which the Minimum Quantity was not delivered.



      10.2 If the performance of this Agreement shall be prevented for a period exceeding three (3)
months from the date of notice given pursuant to Section 10.1 due to an event of Force Majeure, the
Party receiving notice of an event of Force Majeure shall be entitled to terminate all obligations
regarding the supply of Product in the affected Flu Season forthwith by giving written notice to
the other. As regards the supply of Product for all other Flu Seasons during the Term, subject to
Sections 15.3 and 15.4, this Agreement shall continue in full force and effect.



[**] - Confidential or
proprietary information redacted.


14








 





11. WARRANTIES OF IDB AND HSI




      11.1 IDB warrants that:




     11.1.1 the Product supplied to HSI hereunder shall, at the time of delivery to the
Shipping Point, conform in all material respects to the Specifications, including, without
limitation, with respect to design of Product, and such Product will not, at the time of its
delivery to the Shipping Point, be adulterated or misbranded within the meaning of the U.S.
Food, Drug and Cosmetic Act, 21 U.S.C. §301 et seq., as it may be amended from time to time;




     11.1.2 to its actual knowledge as of the Effective Date, it has received no notice from
any third party claiming that the manufacture, use or sale of Product will infringe any
Intellectual Property rights of any third party;




     11.1.3 subject to Sections 3.1 and 7.1, it shall manufacture Product in compliance with
all applicable laws, rules and regulations, including the conditions of the Marketing
Authorization, including current Good Manufacturing Practice;




     11.1.4 it has taken, and during the Term will take, all commercially reasonable action
(as provided in Section 8.3) against any third party claiming any rights to Product which
would conflict with the rights granted to HSI hereunder.




     11.1.5 title to Product will pass to HSI (as provided in Section 5.5) free and clear of
all third party liens, claims, security interests, or other encumbrances;




     11.1.6 it has the full right, power and authority, and has taken all corporate action
necessary, to execute, deliver and perform this Agreement; and




     11.1.7 its execution and delivery of this Agreement does not, and performance by it of
its obligations hereunder will not, constitute a breach of, or conflict with, any agreement,
order, judgment, decree or other arrangement, whether written or oral, to which it is a
party or by which it is bound as of the Effective Date.



      11.2 HSI warrants that:




     11.2.1 its statements to IDB and calculations of the Average Sell Price, the Transfer
Price and the final Purchase Price of all Product supplied by IDB each Flu Season under this
Agreement, and all underlying data, as reported in accordance with Section 2.3 or otherwise
to IDB, shall be accurate statements and calculations of those terms, determined in
accordance with this Agreement (including in Schedule 1), and no discounts or other
concessions directly or indirectly related to HSI’s sales of other products to Other
Distributors or to the same customers that purchase Product shall be applied to or used in
the calculation of the Average Sell Price or to reduce Net Sales Revenue used in calculating
the Average Sell Price, the Transfer Price or the Purchase Price;



[**] - Confidential or
proprietary information redacted.


15








 






     11.2.2 it shall comply fully at its expense with all applicable laws, rules and
regulations in the Territory (including, without limitation, those of the Regulatory
Authority) pertaining to the storage, handling, inventory, marketing, distribution and sale
of Product, and shall market and sell Product only for the uses and applications set forth
in, and in accordance with, the Marketing Authorization;




     11.2.3 it has the full right, power and authority, and has taken all corporate action
necessary, to execute, deliver and perform this Agreement; and




     11.2.4 its execution and delivery of this Agreement does not, and performance by it of
its obligations hereunder will not, constitute a breach of, or conflict with, any agreement,
order, judgment, decree or other arrangement, whether written or oral, to which it is a
party or by which it is bound as of the Effective Date.



      11.3 EXCEPT FOR THE WARRANTIES EXPRESSLY SET FORTH IN SECTIONS 11.1 AND 11.2, NEITHER IDB NOR
HSI MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS, IMPLIED OR OTHERWISE. WITHOUT
LIMITING THE FOREGOING SENTENCE, IDB SPECIFICALLY DISCLAIMS, AND HSI EXPRESSLY WAIVES (i) ANY
EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO
PRODUCT, WHETHER USED ALONE OR IN CONNECTION WITH OTHER SUBSTANCES OR MATERIALS; AND (ii) ANY
LIABILITY WITH RESPECT TO ANY PRODUCT THAT HAS BEEN ALTERED, MODIFIED OR TAMPERED WITH AFTER
DELIVERY TO THE SHIPPING POINT; OR BEEN SUBJECTED TO MISUSE, NEGLIGENCE OR OTHERWISE DAMAGED AFTER
DELIVERY TO THE SHIPPING POINT; OR, AFTER DELIVERY TO THE SHIPPING POINT, HAS BEEN STORED, HANDLED,
OR USED IN A MANNER CONTRARY TO APPLICABLE LAWS OR REGULATIONS OR IDB’S INSTRUCTIONS; OR HAS
EXCEEDED ITS STATED EXPIRATION DATE.



      11.4 EXCEPT AS PROVIDED IN SECTION 12, HSI’S EXCLUSIVE REMEDY FOR BREACH OF ANY WARRANTY BY
IDB UNDER SECTION 11.1.1 IS THE DELIVERY BY IDB, IN ACCORDANCE WITH SECTIONS 5.3 AND 5.4, OF
ADDITIONAL QUANTITIES OF PRODUCT IN REPLACEMENT OF THE PRODUCT THAT, AT THE TIME OF DELIVERY TO THE
SHIPPING POINT, WAS NOT IN COMPLIANCE WITH IDB’S WARRANTY IN SECTION 11.1.1 (“DEFECTIVE PRODUCT”),
OR THE REFUND OF THE PURCHASE PRICE FOR SUCH DEFECTIVE PRODUCT, AT HSI’S OPTION. HSI shall have
the right, which it must exercise in accordance with the provisions of (and subject to the
limitations of) Sections 5.2 and 5.3, to return and demand the replacement of any such Defective
Product to IDB. Provided that HSI gives IDB all assistance reasonably requested by IDB relating to
any recall of Defective Product and is in material compliance with the Product Recall Procedures
and the requirements of the Regulatory Authority and any other applicable legal requirements in
connection therewith (to the extent such requirements are applicable to HSI), IDB shall reimburse
to HSI the costs reasonably incurred by HSI directly in connection with the recall of Defective
Product, including the replacement or destruction of such Defective Product. In all other
circumstances, HSI, not IDB, shall bear the cost of any recall or



[**] - Confidential or
proprietary information redacted.


16








 






replacement of such Defective Product. With respect to any Product recall, the Parties shall
follow the Product Recall Procedure to be set forth in Schedule 5 to this Agreement.



12. INDEMNIFICATION OBLIGATIONS OF IDB AND HSI




      12.1 IDB shall indemnify, defend and hold HSI and its Affiliates, and their respective
directors, officers, employees and agents (“HSI Indemnitees”), harmless from and against any and
all claims, actions, causes of action, liabilities, losses, costs and expenses (including
reasonable attorneys’ fees) incurred thereby or caused thereto arising out of third-party claims
(i.e., claims by parties other than an HSI Indemnitee) relating to Product to the extent that such
claims arise out of or result from (i) any defect in Product at the time it was delivered to the
Shipping Point, where such defect constitutes a breach of IDB’s warranty under Section 11.1.1; (ii)
the failure of IDB to provide disclosure of contraindications, adverse reactions or other
information in Product packaging or labeling as required under applicable laws or regulations;
(iii) any material breach of this Agreement by IDB (including, without limitation, material breach
of its warranties hereunder); (iv) the labeling or packaging of Product by or on behalf of IDB; (v)
the possession, distribution, sale and/or use of Product, including claims of bodily injury, death,
property damage or similar third-party claims; or (vi) the negligence or willful misconduct of IDB;
provided, that, IDB shall have no duty to indemnify, defend or hold harmless any HSI
Indemnitee to the extent HSI, its Affiliates or Other Distributors caused or contributed to losses
or claims (including claims of bodily injury, death, property damage or similar third-party
claims), or to the extent HSI is obligated to indemnify IDB under Section 12.2; and
provided, further, that, without diminishing IDB’s obligations under this Section 12.1,
nothing in this Section 12.1 shall create or imply liability for IDB under other sections of this
Agreement where such liability is expressly disclaimed.



      12.2 HSI shall indemnify, defend and hold IDB and its Affiliates, and their respective
directors, officers, employees and agents (“IDB Indemnitees”), harmless from and against any and
all claims, actions, causes of action, liabilities, losses, costs and expenses (including
reasonable attorneys’ fees) incurred thereby or caused thereto, arising out of third-party claims
(i.e., claims by someone other than an IDB Indemnitee and including claims of bodily injury, death,
property damage or similar third-party claims) relating to Product to the extent that such claims
arise out of or result from (i) any material breach of this Agreement by HSI (including, without
limitation, material breach of its warranties hereunder), (ii) any acts or omissions by or on
behalf of HSI, its Affiliates or Other Distributors or their respective employees, agents or
representatives, which are beyond the scope of HSI’s authorization granted herein or are not in
compliance with the obligations of HSI under this Agreement (including, without limitation, any
use, sale or other disposition of Product or Trademarks in a manner recommended, proposed or
represented by HSI which is contrary to or not in accordance with IDB’s written recommendations,
representations or authorization), or (iii) the negligence or willful misconduct of HSI; provided
that HSI shall have no duty to indemnify, defend or hold harmless any IDB Indemnitee to the extent
IDB is obligated to indemnify HSI under Section 12.1.



      12.3 It shall be a condition of IDB or HSI, as the case may be (the “Indemnifying Party”)
being liable to the other Party (the “Indemnified Party”) and its respective Indemnitees under the
foregoing indemnity obligations that: (i) the Indemnified Party shall notify the Indemnifying
Party in writing of any claim threatened or filed against it or against any of the



[**] - Confidential or
proprietary information redacted.


17








 






Indemnified Party’s Indemnitees promptly after learning of such claim; (ii) the Indemnifying
Party, at its sole cost, shall have the opportunity to assume the direction and control the defense
of such claim or proceeding with counsel of its choosing; (iii) the Indemnified Party shall
cooperate fully with and provide reasonable assistance to the Indemnifying Party and its
representatives and insurers in connection with such claim and (at the expense of the Indemnifying
Party) the mitigation of losses, costs, expenses and liabilities in connection therewith; and (iv)
neither the Indemnified Party nor its Indemnitee(s) shall compromise, settle or take any other
material steps relating to such claim without the prior written approval of the Indemnifying Party
(which shall not to be unreasonably withheld or delayed). The failure of the Indemnified Party to
notify the Indemnifying Party in writing promptly after learning of any such claim or proceeding
shall relieve the Indemnifying Party of any liability to the Indemnified Party under this Agreement
if and solely to the extent the Indemnifying Party can demonstrate that such late notice is
prejudicial to the ability of the Indemnifying Party to defend such action.



13. INSURANCE OBLIGATIONS OF IDB AND HSI




      13.1 Each Party will, at its own expense, maintain, during the Term and for a period of not
less than five (5) years following termination of this Agreement, insurance coverage insuring it
against such of its liabilities arising under its indemnity obligations under this Agreement as are
reasonably insurable, with limits of coverage not less than [**] per occurrence and [**] in the
aggregate. Each Party shall also maintain at its expense such other insurance as may be required
by governmental or statutory authorities (including, without limitation, the Regulatory Authority)
in the Territory. HSI shall be named as an additional insured under the insurance policies
maintained by IDB hereunder, and such policies shall provide for at least thirty (30) days’ prior
written notice to HSI in the event of cancellation or material reduction of coverage.



      13.2 Each Party shall provide the other Party with a certificate of insurance confirming that
such insurance coverage is in place, and confirming that the insurance premiums have been paid,
such certificates to be provided on or before IDB’s first delivery of Product to HSI under this
Agreement and at such other times as a Party may reasonably request.



14. LIMITATION OF LIABILITY




      EXCEPT IN CONNECTION WITH A PARTY’S WILLFUL MISCONDUCT, NEITHER PARTY SHALL BE LIABLE TO THE
OTHER FOR INDIRECT, INCIDENTAL, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES INCLUDING, BUT NOT
LIMITED TO, LOST PROFITS AND LOSS OF GOODWILL, ARISING FROM OR RELATING TO ANY BREACH OF THIS
AGREEMENT (OR ANY DUTY OF COMMON LAW, AND WHETHER OR NOT OCCASIONED BY THE NEGLIGENCE OF A PARTY OR
ITS AFFILIATES), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT NOTHING
IN THIS SECTION 14 IS INTENDED TO, OR DOES, LIMIT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF
EITHER PARTY UNDER SECTION 12; PROVIDED FURTHER THAT, FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS
SECTION IS INTENDED TO, OR DOES, LIMIT HSI’S OBLIGATION UNDER THIS AGREEMENT TO PURCHASE THE
MINIMUM QUANTITY OF PRODUCT FROM IDB AND PAY IDB THE PURCHASE PRICE THEREFOR DURING THE TERM OF



[**] - Confidential or
proprietary information redacted.


18










 





THIS AGREEMENT. NOTHING IN THIS SECTION 14, HOWEVER, SHALL LIMIT EITHER PARTY’S RIGHT TO
CLAIM DIRECT DAMAGES FROM THE OTHER PARTY.




15. TERM AND TERMINATION




      15.1 This Agreement shall take effect on the Effective Date and, subject to earlier
termination in accordance with all other relevant provisions hereof, shall continue through the
conclusion of the 2014/2015 Flu Season regardless of the Commencement Date under Section 7.2, or
such longer time as extended pursuant to Section 10.1 (the “Term”). The Parties may elect in
writing to extend the term of this Agreement on mutually agreeable terms and conditions.



      15.2 Without limiting any other rights of termination specified herein, either Party may
terminate this Agreement by written notice to the other Party (the “Notified Party”) (such
termination being effective immediately on the Notified Party’s receipt of such notice unless
otherwise specified or agreed), if:




     15.2.1 the Notified Party becomes bankrupt or the subject of procedures in bankruptcy,
or under insolvency laws or for reorganization, receivership, liquidation or dissolution,
and such procedures are not terminated within ninety (90) days; or




     15.2.2 the Notified Party commits a material breach of any of the provisions of this
Agreement and fails to remedy such breach within thirty (30) days of receipt of written
notice from the non-breaching Party (or such longer period as the non-breaching Party may
specify in such notice), such notice specifying the breach in detail and requiring it to be
remedied (for the avoidance of doubt, a material breach of this Agreement by HSI includes,
without limitation, HSI’s failure to purchase the Minimum Quantity of Product for any given
Flu Season which is available for purchase by HSI or to pay the Purchase Price therefor).



      15.3 Without limiting any other rights of termination specified herein, HSI may terminate this
Agreement by written notice to IDB (such termination being effective immediately on IDB’s receipt
of such notice unless otherwise specified or agreed), if:




     15.3.1 IDB fails to obtain the initial Marketing Authorization by [**] ; provided,
however, that HSI may exercise this right to terminate only until [**] ; or




     15.3.2 the Marketing Authorization is suspended for one hundred fifty (150) days or
more or is terminated; provided, however, that HSI may exercise this right to terminate only
until the date that is thirty (30) days after the Marketing Authorization is so suspended
(after 150 days) or terminated.




[**] - Confidential or
proprietary information redacted.

19








 





      15.4 Without limiting any other rights of termination specified herein, IDB may terminate this
Agreement by written notice to HSI (such termination being effective immediately on HSI’s receipt
of such notice unless otherwise specified or agreed), if any of the licenses or approvals required
to be maintained by HSI pursuant to Section 7.5 are suspended for one hundred fifty (150) days or
more or are terminated; provided, however, that IDB may exercise this right to terminate only until
the date that is thirty (30) days after it receives notice that such licenses or approvals are so
suspended or terminated.



      15.5 Upon the termination or expiration of this Agreement:




     15.5.1 HSI shall promptly (within thirty (30) days unless otherwise agreed by IDB) send
to IDB, or otherwise dispose of in accordance with IDB’s directions, all samples of Product
and all promotional, advertising and/or sales materials and technical information relating
to Product in the possession or control of HSI, its Affiliates or Other Distributors;




     15.5.2 HSI shall, and shall cause its Affiliates and Other Distributors to, immediately
cease to promote, market, advertise, sell or distribute Product, except only as and to the
extent permitted in Section 15.5.3 below;




     15.5.3 Within three (3) months of termination, except for termination by IDB based on
HSI’s unremedied breach, HSI may sell stocks of Product supplied by IDB to HSI but not yet
sold by HSI, subject to the applicable provisions of this Agreement, and shall dispose of
all remaining Product on hand in accordance with IDB’s directions and applicable laws and
regulations;




     15.5.4 HSI shall reasonably cooperate with IDB and any successor distributor appointed
by IDB with a view to ensuring an orderly transfer of distribution responsibilities;




     15.5.5 Within thirty (30) days after the termination or expiration of this Agreement,
HSI shall furnish to IDB a complete, accurate and current accounting and report of all
transactions subsequent to those shown in the last report to IDB provided in accordance with
Section 2.3, and with such accounting and report shall pay to IDB any remaining amounts due
under this Agreement; and




     15.5.6 The Parties shall comply with Section 9.6 hereof relating to Confidential
Information.



      15.6 The termination or expiration of this Agreement shall be without prejudice to the rights
and obligations of either Party accrued as of the date of such expiration or termination, in
addition to any other remedies that a Party may have under applicable statutory or common law
(subject to the terms, conditions and limitations of this Agreement). Each Parties’ obligations
under Sections 1, 4, 9, 11-16 and 18 (and, as applicable, the Schedules hereto), and such other
sections which, by their context, are intended to survive, shall survive expiration or termination
of this Agreement. Further, for the avoidance of doubt, HSI shall make all payments as are
required in connection with Product delivered by IDB prior to termination of this Agreement,
subject only to HSI’s right to reject such Product in accordance with Sections 5.2 and 5.3.




[**] - Confidential or
proprietary information redacted.


20








 





16. NOTICES




      Any notice given under or in connection with this Agreement shall be in writing and sent by
commercial courier or commercial overnight delivery service (e.g., FedEx, DHL) to the address(es)
of the other Party specified below or such other address as that Party may from time to time
specify in accordance with this Section. A notice shall be deemed delivered upon the date of its
actual receipt.



	 	 	 
	IDB	 	HSI
	 
	 	 
	Chief Executive Officer

	 	Michael Racioppi
	ID Biomedical Corporation

	 	President – Medical Group
	1630 Waterfront Center

	 	Henry Schein, Inc.
	200 Burrard Street

	 	135 Duryea Road
	Vancouver, BC V6C 3L6

	 	Melville, NY 11747
	Canada

	 	USA
	 
	 	 
	With copy to:

	 	With copy to:
	 
	 	 
	Vice President Legal Affairs

	 	General Counsel
	ID Biomedical Corporation of Quebec

	 	Henry Schein, Inc.
	525 Cartier Boulevard West

	 	135 Duryea Road
	Laval, Quebec

	 	Melville, NY 11747
	Canada

	 	USA






17. ASSIGNMENT




      Neither Party may assign this Agreement or any of its rights, duties or obligations hereunder
without the prior written consent of the other Party, which consent shall not be unreasonably
withheld or delayed; provided that either Party may assign (i) any of its rights, duties or
obligations hereunder to any of its Affiliates and (ii) this Agreement and its rights, duties and
obligations hereunder to a successor entity in connection with the sale of all or substantially all
of its assets or the merger, acquisition or other consolidation of such Party with or into another
party, and the other Party’s consent shall not be required hereunder in connection therewith. This
Agreement shall be binding upon and inure to the benefit of the permitted assigns and successors in
interest of the respective Parties.



18. GOVERNING LAW, JURISDICTION AND VENUE




      This Agreement is governed by and shall be construed in accordance with the laws of the United
States of America and the State of New York, without respect to their choice-of-law provisions.
The Parties shall attempt in good faith to resolve any disputes in a voluntary, amicable and
expeditious manner. In the event they are unable to resolve any such disputes in such manner, the
Parties hereby submit to the exclusive jurisdiction of the state and federal courts located in the
County or City of New York, USA, which shall be the sole and exclusive venue for the resolution of
any disputes based on or arising out of this Agreement; provided that a Party may seek injunctive
relief from any court of competent jurisdiction as necessary to



[**] - Confidential or
proprietary information redacted.

21








 






protect its rights under this Agreement pending final resolution of a dispute before such
courts in New York.



19. MISCELLANEOUS




      19.1 [**]



      19.2 Each Party acknowledges that in entering into this Agreement it does not do so on the
basis of, and does not rely on, any representation, warranty or other provision except as expressly
provided herein, and all conditions, warranties or other terms implied by statute or common law are
hereby excluded to the fullest extent permitted by law.



      19.3 All Schedules to this Agreement are hereby incorporated into this Agreement by reference.
This Agreement and such Schedules constitute the entire Agreement between the Parties and
supersede all previous communications, representations, agreements or understandings, whether oral
or written, between the Parties with respect to the subject matter hereof.



      19.4 Nothing contained in this Agreement shall or be deemed to constitute a partnership or a
relationship of principal and agent, employer and employee or a joint venture between the Parties,
and neither Party shall bind or conduct itself in a manner to suggest it has authority to bind the
other in any way except as expressly permitted in this Agreement. The relationship of IDB and HSI
established by this Agreement is that of independent contractors, and nothing contained in this
Agreement shall be construed to give either Party the power to direct or control the day-to-day
activities of the other. All sales and other agreements between HSI and HSI’s customers are HSI’s
exclusive responsibility and shall have no effect on HSI’s obligations under this Agreement.



      19.5 To be effective, any amendment to or waiver of any provision of this Agreement must be
made in writing and signed by a duly authorized representative of each Party. The failure on the
part of either Party to exercise or enforce any right under this Agreement shall not be deemed to
be a waiver of any such right or similar subsequent rights or operate to bar the exercise of
enforcement thereof at anytime or times thereafter.



      19.6 All dollar amounts set forth in this Agreement are U.S. Dollars.



      19.7 If any court or other competent authority holds any provision of this Agreement to be
void or unenforceable in whole or part, this Agreement shall continue to be valid as to the other
provisions and the remainder of the affected provision.



      19.8 This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original and all of which together shall constitute one and the same instrument.



[Signatures on Next Page]


[**] - Confidential or
proprietary information redacted.



22








 







      IN WITNESS whereof this Agreement has been executed and delivered by the duly authorized
representatives of the Parties as of the Effective Date first above written.



	 	 	 
	Signed for and on behalf of

	 	Signed for and on behalf of
	 
	 	 
	ID BIOMEDICAL CORPORATION

	 	HENRY SCHEIN, INC.
	 
	 	 
	 
	 	 
	 
	 	 
	 

	 	 
	Full Name

	 	Full Name
	 
	 	 
	 
	 	 
	 

	 	 
	Title

	 	Title
	 
	 	 
	 
	 	 
	 

	 	 
	Signature

	 	Signature
	 
	 	 
	 
	 	 
	 

	 	 
	Date

	 	Date





[**] - Confidential or
proprietary information redacted.



23








 







SCHEDULE 1




MINIMUM QUANTITY; PURCHASE PRICE AND ADJUSTMENT;

RESALE TO OTHER DISTRIBUTORS; AND PAYMENT TERMS




1. ORDER DETAILS*




      *Beginning with respect to the first Flu Season commencing on or after the Commencement
Date:



	 	 	 
	Total Minimum Quantity per Flu Season	 	Delivery Date per Flu Season
	 
	 	 
	[**], the Minimum Quantity
per Flu Season to be supplied
by IDB and purchased by HSI
shall be the lesser of (i)
[**] doses of Product
(“Minimum Doses”) or (ii)
[**] percent (“Minimum
Percentage”) of IDB’s
production capacity for
Product for sale or
distribution in the Territory
for such Flu Season (after
fulfilling commitments to the
Government of Canada), [**].

	 	IDB will use commercially reasonable
efforts to deliver and obtain releases
for [**] of the Minimum Quantity by
[**], and for [**] of the Minimum
Quantity by [**] as provided in
Section 3.7 of the Agreement.






2. PRICES





(A) Purchase Price. Subject to Paragraphs 2(B) and 2(C) below, the Purchase Price
to be paid by HSI to IDB for Product supplied under this Agreement shall be:




[**]




(B) Transfer Price and Subsequent Adjustment. HSI shall pay a Transfer Price (as
defined below) to IDB for all doses of Product delivered by IDB to HSI and released by the
Regulatory Authority for a given Flu Season. As used in this Agreement, “Transfer Price”
shall mean




[**]




To determine the final Purchase Price due, such Transfer Price shall be subject to the
following adjustments




[**]




(C) Minimum Purchase Price.




[**]




(D) Reconciliation by February 28.



[**] - Confidential or
proprietary information redacted.



1








 






[**]



3. RESALE TO OTHER DISTRIBUTORS





HSI shall not in any one Flu Season resell Product to Other Distributors in an amount
greater, in the aggregate, than the lesser of (i) [**] doses of Product or (ii) [**]
percent of the total Product supplied by IDB to HSI for that Flu Season; [**] As a
condition of any such sale by HSI to Other Distributors, [**].



4. PAYMENT DETAILS





[**]



5. DEFAULT INTEREST RATE





[**]



[**] - Confidential or
proprietary information redacted.



2








 





SCHEDULE 2




TRADEMARK(s)




	 	 	 	 	 
	Trademark	 	Territory	 	Registered No.
	FLUVIRAL

	 	Canada	 	 





[**] - Confidential or
proprietary information redacted.


3








 





SCHEDULE 3




COMMITMENTS TO GOVERNMENT OF CANADA




      As described in Section 3.2, IDB has certain contractual commitments to the Government of
Canada requiring IDB to provide (i) an annual supply of Product to the Government of Canada and
(ii) a supply of Product in the event the Government of Canada declares an influenza pandemic. The
Minimum Quantity of Product to be supplied by IDB to HSI under this Agreement is subject to IDB’s
commitments to the Government of Canada.



      Other than in the case of a pandemic, the maximum amount of Product that IDB shall reserve for
supply to the Canadian government is, and shall in no event be greater than, 12 million doses per
Flu Season.



[**] - Confidential or
proprietary information redacted.



1








 





SCHEDULE 4




ADVERSE REACTION REPORTING




      [HSI and IDB shall mutually agree upon an adverse reaction reporting procedure, which shall be
in accordance with all applicable laws and regulations, as promptly as practicable following
receipt of appropriate Marketing Authorization for Product in the Territory]



[**] - Confidential or
proprietary information redacted.


1








 







SCHEDULE 5




PRODUCT RECALL PROCEDURE




      [HSI and IDB shall mutually agree upon a Product recall procedure, which shall be in
accordance with all applicable laws and regulations, as promptly as practicable following receipt
of Marketing Authorization for Product in the Territory]


[**] - Confidential or
proprietary information redacted.


1